NCT07108036View on ClinicalTrials.gov

A Study to Assess Anktiva in Patients With Long Covid-19.

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Long COVID

Interventions

DRUG

N-803 (IL-15 Superagonist)

N-803 administered subcutaneously.

Trial Locations (1)

94110

University of California - San Francisco, San Francisco

Sponsors

Lead Sponsor

ImmunityBio, Inc.

All Listed Sponsors

lead

ImmunityBio, Inc.

INDUSTRY